CHC Healthcare Group (4164) AI Stock Analysis

CHC Healthcare Group

(TWSE:4164)

Select Model

Rating:60Neutral

Price Target:TWD 26.00▲(4.42% Upside)

Action:initiatedcoverage

Date:11/10/26

The score is supported by a reasonably solid balance sheet, improving revenue, and an attractive dividend yield. Weak profitability, inconsistent cash-flow conversion, and bearish technical trends weigh materially on the overall score.

Positive Factors

Revenue ReboundRevenue returning to growth in 2025, alongside reported 11.8% revenue growth, indicates business activity recovered after the 2024 decline. If sustained, renewed top-line expansion can support operating scale and provide a foundation for rebuilding earnings over the coming quarters.

Negative Factors

Margin CompressionThe sustained decline in gross, operating, and net margins shows that revenue is producing substantially less profit than in earlier years. Persistent margin pressure can limit reinvestment, weaken earnings quality, and make future profit recovery dependent on improved cost or pricing performance.

CHC Healthcare Group (4164) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 4.93B
Dividend Yield: 4.45%
Average Volume (3M): 355.92K
Price to Earnings (P/E): 21.8
Beta (1Y): 0.42
Revenue Growth: 11.83%
EPS Growth: 27.86%
Country: TW
Employees: 160
Sector: General
Sector Strength: 55
Industry: Medical - Distribution

CHC Healthcare Group Business Overview & Revenue Model

Company Description

Established in Taipei, Taiwan, in 1977, the CHC Healthcare Group delivers a wide array of healthcare management services both within Taiwan and globally. Its core activities involve the distribution, installation, maintenance, and leasing of medical...

CHC Healthcare Group Financial Statement Overview

Summary

Revenue, equity, leverage, operating cash flow, and free cash flow improved in 2025. However, compressed margins, low ROE, and inconsistent free cash flow conversion limit the score.

Income Statement

62Positive

Balance Sheet

68Positive

Cash Flow

60Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Mar 2023	Dec 2021
Income Statement
Total Revenue	4.65B	4.40B	3.60B	3.88B	2.97B	2.44B
Gross Profit	1.25B	1.15B	759.13M	1.07B	902.31M	849.48M
EBITDA	1.11B	1.06B	954.33M	1.24B	1.05B	1.01B
Net Income	225.96M	186.28M	168.38M	418.87M	356.57M	381.63M
Balance Sheet
Total Assets	16.18B	15.63B	14.21B	13.61B	12.83B	12.57B
Cash, Cash Equivalents and Short-Term Investments	1.53B	1.85B	1.73B	2.03B	1.72B	1.92B
Total Debt	5.81B	5.43B	5.74B	5.21B	5.04B	4.98B
Total Liabilities	8.29B	7.55B	7.51B	6.84B	6.43B	6.25B
Stockholders Equity	7.47B	7.63B	6.30B	6.46B	6.14B	6.08B
Cash Flow
Free Cash Flow	-20.56M	159.96M	-331.72M	386.92M	-25.97M	178.70M
Operating Cash Flow	554.20M	1.03B	99.37M	962.59M	656.66M	692.79M
Investing Cash Flow	-1.19B	-1.60B	-544.86M	-500.46M	-339.98M	-990.35M
Financing Cash Flow	861.00K	720.88M	188.24M	-42.05M	-346.45M	415.06M

CHC Healthcare Group Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4164 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4166	70Outperform	TWD 5.47B	22.78	―	―	―	―
TW:4126	68Neutral	TWD 5.39B	12.54	―	6.00%	1.32%	7.25%
TW:4164	60Neutral	TWD 4.79B	21.84	―	4.45%	11.83%	27.86%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:3176	42Neutral	TWD 4.62B	-16.65	―	―	1.11%	-94.39%
TW:4737	39Underperform	TWD 4.18B	-13.55	―	―	-9.37%	-132.26%

* General Sector Average

Performance Comparison

TW:4164 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4164	CHC Healthcare Group	24.90	-15.58	-38.48%
TW:3176	Medigen Biotechnology Corporation	30.10	0.15	0.50%
TW:4126	Pacific Hospital Supply Co., Ltd.	75.00	-8.51	-10.19%
TW:4166	Orient Pharma Co., Ltd.	22.55	-1.95	-7.96%
TW:4737	Bionime Corporation	55.70	-6.00	-9.72%
TW:7902	Uwell Biopharma Inc.	25.45	-2.15	-7.79%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

CHC Healthcare Group AI Stock Analysis